Innovation, Execution, and Equity in RNA-Based Women’s Health
In this episode, Seuss+ CEO and Co-Founder Sabine Hutchison sits down with Klaas Zuideveld, CEO of Versameb, to discuss the scientific, clinical, and societal implications of RNA-based therapies targeting stress urinary incontinence, a condition affecting hundreds of millions of women worldwide. Klaas shares his insights into Versameb’s lead program, VMB-100, and how their regenerative mRNA platform aims to transform women’s health by offering scalable, minimally invasive solutions. From novel anatomy discoveries and IND clearance to market misconceptions and funding barriers, this conversation unpacks the urgency, and opportunity of driving innovation in underserved therapeutic areas. Together, they explore why executional clarity and equity are essential for unlocking the future of RNA in clinical development.
Liked this episode? Get our monthly LinkedIn newsletter directly to your inbox.
Sign up to stay up-to-date with the business of science, industry news, developing trends, and key insights.